Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human ascending-dose study of STR-324 in healthy volunteers
NL-OMON46459Phase 1Completed
- Sponsor
- Stragen
- Start
- Feb 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain comparing STR-324 infusion with Placebo infusion (2 arms). Primary endpoints: Treatment-emergent adverse events, Clinical laboratory safety and 5 more. Started Feb 2018; status: completed.
02
Drugs
STR-324
03
Conditions
pain
Beyond the preview
Go deeper on NL-OMON46459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46459.